Article Details
Retrieved on: 2021-06-11 21:45:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Truist Securities increased their target price on NovoCure from $132.00 to $142.00 and gave the company a "hold" rating in a report on Monday, April ...
Article found on: www.marketbeat.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here